Journal: The Journal of International Medical Research

Article Title: Identification of therapeutic targets and prognostic biomarkers of the ephrin receptor subfamily in pancreatic adenocarcinoma

doi: 10.1177/03000605231218559

Figure Lengend Snippet: EphA2 mRNA expression profiles of various tumor samples and paired normal tissues. The height of the bar represents the median expression level (in transcripts per million (TPM)) in each tumor or normal tissue type.

Article Snippet: A mouse anti-EphA2 antibody (MAB3035, 1:50, R&D Systems, Boston, MA, USA) was used.

Techniques: Expressing

Journal: The Journal of International Medical Research

Article Title: Identification of therapeutic targets and prognostic biomarkers of the ephrin receptor subfamily in pancreatic adenocarcinoma

doi: 10.1177/03000605231218559

Figure Lengend Snippet: EphA2 expression patterns in pancreatic adenocarcinoma (PAAD) patients. (a) EphA2 transcriptional levels in PAAD and normal pancreatic tissues and (b) EphA2 mRNA levels in PAAD primary tumors and normal tissues.

Article Snippet: A mouse anti-EphA2 antibody (MAB3035, 1:50, R&D Systems, Boston, MA, USA) was used.

Techniques: Expressing

Journal: The Journal of International Medical Research

Article Title: Identification of therapeutic targets and prognostic biomarkers of the ephrin receptor subfamily in pancreatic adenocarcinoma

doi: 10.1177/03000605231218559

Figure Lengend Snippet: Associations between pancreatic adenocarcinoma (PAAD) clinical pathological stage and EphA2 expression.

Article Snippet: A mouse anti-EphA2 antibody (MAB3035, 1:50, R&D Systems, Boston, MA, USA) was used.

Techniques: Expressing

Journal: The Journal of International Medical Research

Article Title: Identification of therapeutic targets and prognostic biomarkers of the ephrin receptor subfamily in pancreatic adenocarcinoma

doi: 10.1177/03000605231218559

Figure Lengend Snippet: The prognostic value of EphA2 expression in pancreatic adenocarcinoma (PAAD) patients. Kaplan–Meier plots are shown for (a) overall survival and (b) disease-free survival.

Article Snippet: A mouse anti-EphA2 antibody (MAB3035, 1:50, R&D Systems, Boston, MA, USA) was used.

Techniques: Expressing

Journal: The Journal of International Medical Research

Article Title: Identification of therapeutic targets and prognostic biomarkers of the ephrin receptor subfamily in pancreatic adenocarcinoma

doi: 10.1177/03000605231218559

Figure Lengend Snippet: EphA2 promoter DNA methylation patterns in pancreatic adenocarcinoma (PAAD) primary tumors and normal tissues.

Article Snippet: A mouse anti-EphA2 antibody (MAB3035, 1:50, R&D Systems, Boston, MA, USA) was used.

Techniques: DNA Methylation Assay

Journal: The Journal of International Medical Research

Article Title: Identification of therapeutic targets and prognostic biomarkers of the ephrin receptor subfamily in pancreatic adenocarcinoma

doi: 10.1177/03000605231218559

Figure Lengend Snippet: Correlations of immune cell infiltration and EphA2 expression in pancreatic adenocarcinoma (PAAD) patients.

Article Snippet: A mouse anti-EphA2 antibody (MAB3035, 1:50, R&D Systems, Boston, MA, USA) was used.

Techniques: Expressing

Journal: The Journal of International Medical Research

Article Title: Identification of therapeutic targets and prognostic biomarkers of the ephrin receptor subfamily in pancreatic adenocarcinoma

doi: 10.1177/03000605231218559

Figure Lengend Snippet: Multivariate Cox proportional risk model of pancreatic adenocarcinoma (PAAD).

Article Snippet: A mouse anti-EphA2 antibody (MAB3035, 1:50, R&D Systems, Boston, MA, USA) was used.

Techniques: Expressing

Journal: The Journal of International Medical Research

Article Title: Identification of therapeutic targets and prognostic biomarkers of the ephrin receptor subfamily in pancreatic adenocarcinoma

doi: 10.1177/03000605231218559

Figure Lengend Snippet: Protein-protein interaction (PPI) analysis of EphA2 in pancreatic adenocarcinoma (PAAD) patients. (a) PPI network of EphA2. (b) Potential functions of the proteins of interest and (c) Molecular complex detection components identified in the gene lists.

Article Snippet: A mouse anti-EphA2 antibody (MAB3035, 1:50, R&D Systems, Boston, MA, USA) was used.

Techniques:

Journal: The Journal of International Medical Research

Article Title: Identification of therapeutic targets and prognostic biomarkers of the ephrin receptor subfamily in pancreatic adenocarcinoma

doi: 10.1177/03000605231218559

Figure Lengend Snippet: Functional enrichment analysis of EphA2 in pancreatic adenocarcinoma (PAAD) patients.

Article Snippet: A mouse anti-EphA2 antibody (MAB3035, 1:50, R&D Systems, Boston, MA, USA) was used.

Techniques: Functional Assay

Journal: The Journal of International Medical Research

Article Title: Identification of therapeutic targets and prognostic biomarkers of the ephrin receptor subfamily in pancreatic adenocarcinoma

doi: 10.1177/03000605231218559

Figure Lengend Snippet: Analysis of EphA2 protein expression using immunohistochemistry (IHC) in tissue samples from pancreatic adenocarcinoma (PAAD) patients. Representative images are shown at 100x magnification. (a) High EphA2 protein expression in pancreatic cancer tissue and (b) Low EphA2 protein expression in paracancerous tissue.

Article Snippet: A mouse anti-EphA2 antibody (MAB3035, 1:50, R&D Systems, Boston, MA, USA) was used.

Techniques: Expressing, Immunohistochemistry

Journal: Frontiers in Immunology

Article Title: Blocking of EphA2 on Endometrial Tumor Cells Reduces Susceptibility to Vδ1 Gamma-Delta T-Cell-Mediated Killing

doi: 10.3389/fimmu.2021.752646

Figure Lengend Snippet: Phenotyping and surface expression of EphA2, MICA, MICB, CD112, CD155, and B7-H6 on target endometrial tumor cell lines including Ishikawa, KLE, and RL95-2 by flow cytometry. (A) Representative plots are shown as histograms of the unstained controls (red) and histograms representing the stained samples (blue). Data are expressed as mean fluorescence intensity (MFI, x -axis) versus number of cells ( y -axis). (B) Summary of the EphA2 expression analyzed by the real-time qPCR in a panel of tumor cell lines presented as fold gene expression.

Article Snippet: In the blocking experiments, the EphA2 antibody (R&D Systems, clone 371805) and ALW-II-41-27 EphA2 inhibitor (10 μM, 1 μM) or DMSO as a control were added to tumor cultures prior the cytotoxicity assays.

Techniques: Expressing, Flow Cytometry, Staining, Fluorescence, Gene Expression

Journal: Frontiers in Immunology

Article Title: Blocking of EphA2 on Endometrial Tumor Cells Reduces Susceptibility to Vδ1 Gamma-Delta T-Cell-Mediated Killing

doi: 10.3389/fimmu.2021.752646

Figure Lengend Snippet: The inhibition of Vδ1 T-cell-mediated killing by blocking of EphA2 expression on endometrial tumor cells. The target cells were preincubated with the EphA2 antibody prior to 4 h cytotoxicity assays and the specific lysis of KLE (A) and RL95-2 (B) cells was determined at 5:1 and 10:1 E:T ratios. Summary data of specific lysis and cytotoxicity reduction in the presence of EphA2 antibody is shown as the mean ± SD of independent experiments performed in duplicates (HD numbered anonymously). (C) Analysis of the in vitro effects of the small-molecule inhibitor ALW-II-41-27 at 1 and 10 µM on KLE endometrial tumor cells. Dose-dependent inhibition of cytotoxicity by Vδ1 T cells is shown at 5:1 (pale grey bars) and 10:1 (dark grey bars) E:T ratios. (D) Vδ1 T-cell-mediated killing of EphA2-negative Ishikawa endometrial cell line was analyzed at 10:1 E:T with/without the presence of small-molecule inhibitor ALW-II-41-27 (1 µM) and is shown as the mean ± SD of independent experiments performed in duplicates.

Article Snippet: In the blocking experiments, the EphA2 antibody (R&D Systems, clone 371805) and ALW-II-41-27 EphA2 inhibitor (10 μM, 1 μM) or DMSO as a control were added to tumor cultures prior the cytotoxicity assays.

Techniques: Inhibition, Blocking Assay, Expressing, Lysis, In Vitro

Journal: Frontiers in Immunology

Article Title: Blocking of EphA2 on Endometrial Tumor Cells Reduces Susceptibility to Vδ1 Gamma-Delta T-Cell-Mediated Killing

doi: 10.3389/fimmu.2021.752646

Figure Lengend Snippet: The inhibition of specific lysis of EphA2-positive RL-95 endometrial cell line. (A) Freshly sorted Vδ1 T cells were co-cultured with tumor targets for 4 h, and cytotoxicity was determined at 5:1 E:T ratio for the wild type (WT, white bars) and the EPHA2 knockout (KO, grey bars) shown as the mean ± SD of independent experiments performed in duplicates (HD numbered anonymously). (B) Similarly, inhibition of specific lysis by Vδ1 T cells was determined at 10:1 E:T ratio for the wild type (WT, white bars) and the EPHA2 knockout (KO, dark grey bars) with/without the presence of small-molecule inhibitor ALW-II-41-27 (1uM) and is shown as the mean ± SD of independent experiments performed in duplicates. (C) The EPHA2 knockouts of renal tumor cell line A-498 (grey bars) and colon adenocarcinoma tumor cell line HT-29 (D) were generated and specific lysis was compared with WT cells (white bars) at 10:1 ratio. Significant inhibition of cell lysis mediated by tumor-reactive Vδ1 T cells was shown as the mean ± SD of independent experiments performed in duplicates.

Article Snippet: In the blocking experiments, the EphA2 antibody (R&D Systems, clone 371805) and ALW-II-41-27 EphA2 inhibitor (10 μM, 1 μM) or DMSO as a control were added to tumor cultures prior the cytotoxicity assays.

Techniques: Inhibition, Lysis, Cell Culture, Knock-Out, Generated